Another study [86] determined the efficacy of Paclitaxel loaded in sterically-stabilized, biocompatible, and biodegradable phospholipid nanomicelles (SSMM) and actively-targeted, vasoactive, intestinal, peptide-grafted SSMM (SSMM-VIP) in circumventing P-glycoprotein (P-gp)-mediated Paclitaxel resistance in BC19/3 cells, a human breast cancer cell line that expresses >10-fold higher P-gp than its parental sensitive cell line, MCF-7. This evidence concerns the gene PGP and breast cancer.